Association between inflammatory biomarkers and thin-cap fibroatheroma detected by optical coherence tomography in patients with coronary heart disease

Kohei Koyama1, Kihei Yoneyama1, Takanobu Mitarai1, Yuki Ishibashi1, Eiji Takahashi2, Ken Kongoji1, Tomoo Harada1, Yoshihiro J. Akashi1

1 Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
2 St. Marianna University School of Medicine, Yokohama-city Seibu Hospital, Yokohama, Japan

Submitted: 31 May 2014
Accepted: 15 June 2014

Arch Med Sci 2015; 11, 3: 505–512
DOI: 10.5114/aoms.2015.52352
Copyright © 2015 Termedia & Banach

Abstract

Introduction: The relationship between plaque morphology detected by optical coherence tomography (OCT) and inflammatory biomarkers is not well known.

Material and methods: This study included 47 patients with ischemic heart disease (22 patients with acute coronary syndrome and 25 patients with effort angina pectoris) who underwent percutaneous coronary intervention (PCI). Before PCI, peripheral blood levels of the inflammatory biomarkers high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) were measured. The OCT can detect thin-cap fibroatheroma (TCFA), a lesion with high potential for adverse cardiac events. We investigated the relationships between TCFA in culprit lesions detected by OCT and the peripheral blood levels of these biomarkers.

Results: We observed 12 lesions detected as TCFA. The natural logs of hs-CRP and IL-6 levels in the TCFA group were higher than those in the non-TCFA group (hs-CRP 0.87 (–0.96 to 0.87) vs. –0.47 (–0.92 to 0.30) mg/l, p = 0.027; and IL-6 1.63 (0.63–3.23) vs. 0.53 (–0.21 to 1.05) pg/dl, p = 0.005, respectively). In multivariate logistic regression analysis, log IL-6 was an independent predictor for TCFA detected by OCT (log IL-6, 0.970 pg/dl, p = 0.023). Receiver operating characteristic curve analysis confirmed that IL-6, compared to hs-CRP, has a higher area under the curve for predicting TCFA (0.783 vs. 0.715, respectively).

Conclusions: Peripheral blood levels of both hs-CRP and IL-6 were associated with TCFA, as detected by OCT. Moreover, IL-6 has a higher potential than hs-CRP for predicting TCFA.

Key words: vulnerable plaque, biomarkers, optical coherence tomography.

Introduction

Since the 1990s, it has been gradually accepted that the inflammation mechanism is closely associated with the progress and instability of atherosclerosis [1, 2]. Recent advances have led to a better understanding of the association between inflammatory biomarkers and progress of atherosclerosis [3–5]. Several investigators have examined a variety of circulating inflammation markers to predict the risk of future vascular events.
Among them, C-reactive protein (CRP), which has been the best studied, is the most consistently related to future risk [6, 7]. According to recent studies, interleukin-6 (IL-6) is also known as a predictor of future cardiac events [6, 8].

Recently developed imaging modalities provide precise and accurate evaluations of culprit lesions in coronary arteries. Optical coherence tomography (OCT) has approximately 10 times higher (15–20 μm) resolution for cross-sectional images of vessels than that of intravascular ultrasound [9] and can measure fibrous cap thickness and detect lipid plaques and thrombi with higher sensitivity and specificity [9–11]. Therefore, OCT can detect thin-cap fibroatheroma (TCFA), a lesion with high potential for plaque rupture, the most common cause of acute coronary thrombosis, which can lead to severe critical outcomes, including sudden death [12, 13]. However, the relationship between plaque morphology and inflammatory biomarkers has not been fully elucidated in vivo.

This study aimed to evaluate the correlation between peripheral levels of inflammatory biomarkers, including high-sensitivity C-reactive protein reaction (hs-CRP) and IL-6, and TCFA, as detected on OCT.

**Material and methods**

**Study population**

From August 2011 to July 2012, 50 cardiovascular disease patients who underwent percutaneous coronary intervention (PCI) at our hospital were enrolled in this study. There were 24 acute coronary syndrome (ACS) patients, including 13 patients with acute myocardial infarction (AMI), 11 patients with unstable angina pectoris (UAP), and 26 patients with stable angina pectoris (SAP). The AMI was diagnosed in patients with continuous chest pain, changes in serial electrocardiographic findings, and abnormal levels of cardiac enzymes (creatinine kinase-MB or troponin-I). The UAP was diagnosed if there was angina at rest or a crescendo electrocardiogram pattern without increase in cardiac enzyme levels. The SAP was diagnosed if there was no change in frequency, duration, and intensity of angina symptoms within 6 weeks preceding the intervention. We excluded patients who had left main coronary artery disease, multivessel disease, congestive heart failure, renal dysfunction with baseline serum creatinine more than 1.5 mg/dl, a residual infection or other inflammatory diseases within the previous 6 months, collagen disease, or malignant disease. Patients who were treated with steroids were also excluded. A culprit lesion of the coronary artery was identified by a combination of echocardiographic left ventricular abnormalities, angiographic findings, and cardiac scintigraphic defects. We divided our patients into 2 groups, those who had a TCFA (TCFA group) and those who did not (non-TCFA group), and investigated the relationship between TCFA in culprit lesions and inflammatory biomarkers. This study was approved by our hospital’s ethics committee, and all patients provided written informed consent before participation.

**Measurement of plasma biomarkers**

In ACS (UAP and AMI) patients, blood samples were collected from an upper limb vein before emergent coronary angiography, and the blood was collected from the same vein on the second morning after admission in the SAP group. For plasma preparation, 2Na-EDTA was added to whole blood. After that, the blood sample was immediately centrifuged at 3000 rpm for 10 min, and the plasma was obtained and stored at −80°C until biomarker detection testing. The hs-CRP level in plasma was assayed according to the manufacturer’s protocols (N-Latex CRP II; Siemens Healthcare Diagnostics, Malvern, PA, USA). The IL-6 was measured by commercially available ELISA kits, according to the protocols of the manufacturer (R&D Systems, Minneapolis, MN, USA).

**Optical coherence tomography imaging**

The OCT examinations were performed before PCI. All patients were administered 100 U/kg heparin before the procedure. A 6 Fr or 7 Fr guiding catheter was introduced into the coronary artery, and nitroglycerin (0.1–0.2 mg) was administered through the guiding catheter. The OCT images were obtained with a time-domain (M3 OCT system; LightLab Imaging/St Jude Medical, Westford, MA, USA) or a frequency-domain OCT C7XR system and Dragon Fly catheter (LightLab Imaging/St Jude Medical). In the M3 OCT system, a 0.016-inch OCT imaging catheter (LightLab Imaging) was inserted into the distal end of the culprit lesion through the central lumen in an occlusion balloon catheter (Helios; Avantec Vascular Corp, Sunnyvale, CA, USA). While the images were acquired during a pullback of the catheter, the occlusion balloon, which was positioned at the proximal site of the culprit lesion, was inflated to 0.5–0.7 atm, and Ringer’s lactate solution was infused at 0.6–0.8 ml/s. When the target lesion was located close to the ostium of the coronary artery, a continuous-flushing nonocclusive technique was used for a detailed evaluation. Low-molecular-weight dextran L (Otsuka Pharmaceutical Factory, Tokushima, Japan) was directly infused through the guiding catheter at 3.0–4.0 ml/s to remove blood from the coronary artery. The OCT
pullback speed was 1.0 mm/s. Furthermore, in the C7XR system, a 2.7 Fr OCT imaging catheter was carefully inserted into the distal end of the culprit lesion. The automated pullback system was performed at 20 mm/s while blood was displaced by flushing with contrast medium or dextran using the guiding catheter. The culprit lesions in patients with ACS with a Thrombolysis in Myocardial Infarction (TIMI) flow grade of 0–2 were evaluated after thrombectomy using the thrombus aspiration catheter (Thrombuster III; Kaneka Medical Products, Osaka, Japan). In this study, we evaluated the presence of plaque rupture, coronary thrombus, and TCFA in the culprit lesion. A plaque rupture was defined as a plaque containing a cavity that communicated with the lumen with an overlying residual fibrous cap fragment [6]. Intracoronary thrombus was identified by the mass images protruding into the vessel lumen from the vessel wall [11]. The TCFA was defined as a lipid-rich plaque (signal-poor and attenuated area with 2 or more quadrants) of the vessel lumen with the thinnest part of the fibrous cap measuring ≤65 µm [12]. In nonruptured plaques, the thinnest fibrous cap thickness was defined as the distance from the arterial lumen to the inner border of the lipid pool. In ruptured plaques, the thinnest fibrous cap thickness was defined as the minimum residual fibrous cap identified as a flap between the arterial lumen and the cavity caused by the plaque [13, 14]. An average of 3 measurements of the minimum fibrous cap thickness in the culprit plaque were taken (Figures 1 and 2). These plaque morphologies were observed by 2 independent observers who were blinded to the clinical presentation. The OCT images were digitalized and analyzed using proprietary software from LightLab Imaging.

**Statistical analysis**

SPSS version 20 (IBM, Chicago, IL, USA) was used for all analyses. All categorical variables are expressed as frequencies and percentages and were compared using the χ² or Fisher’s exact test, as appropriate. Continuous data are expressed as mean ± standard deviation for normally distributed variables or median (25th to 75th percentiles) for non-normally distributed variables. Differences between continuous variables were compared using unpaired Student’s t-test or the Mann-Whitney tests, as appropriate. The distribu-

![Figure 1](image1.png)
tion normality was tested with the Shapiro-Wilk test. Stepwise multiple logistic regression analysis was performed to assess independent predictors for TCFA. Receiver operating characteristic (ROC) curves were used to determine the true-positive rate (sensitivity) and false-positive rate (1 – specificity) of serum biomarkers. A *p* value < 0.05 was considered as statistically significant.

**Table I.** Patient characteristics

| Parameter | TCFA group (n = 12) | Non-TCFA group (n = 35) | Value of *p* |
|-----------|---------------------|-------------------------|--------------|
| Age, mean ± SD [years] | 67 ±12 | 67 ±11 | 0.861 |
| Female, n (%) | 0 (0) | 8 (23) | 0.093 |
| BMI, mean ± SD [kg/m²] | 23.8 ±3.3 | 22.8 ±2.9 | 0.289 |
| Hypertension, n (%) | 8 (67) | 27 (77) | 0.471 |
| Dyslipidemia, n (%) | 8 (67) | 26 (74) | 0.713 |
| DM, n (%) | 4 (33) | 10 (29) | 0.731 |
| Smoking, n (%) | 7 (58) | 24 (69) | 0.725 |
| MI history, n (%) | 2 (17) | 3 (9) | 0.59 |
| Statin use, n (%) | 2 (17) | 13 (5) | 0.288 |
| HbA1c, mean ± SD (%) | 6.1 ±1.6 | 5.7 ±0.8 | 0.696 |
| HDL, mean ± SD [mg/dl] | 48 ±15 | 46 ±11 | 0.800 |
| LDL, mean ± SD [mg/dl] | 107 ±34 | 103 ±28 | 0.780 |
| Diagnosis: | | | |
| SAP, n (%) | 2 (17) | 23 (66) | 0.003 |
| UAP, n (%) | 3 (25) | 7 (20) | 0.7 |
| AMI, n (%) | 5 (41) | 7 (58) | 0.005 |
| Culprit lesion: | | | 0.969 |
| LAD, n (%) | 6 (50) | 17 (48) | 0.933 |
| LCX, n (%) | 3 (25) | 8 (23) | 0.880 |
| RCA, n (%) | 3 (25) | 10 (29) | 0.811 |
| Laboratory findings, median (interquartile range): | | | |
| WBC, 10⁹/l | 7.85 (5.28–10.40) | 6.10 (5.30–7.60) | 0.121 |
| hs-CRP [mg/l] | 2.62 (0.55–11.40) | 0.63 (0.40–1.35) | 0.027 |
| IL-6 [pg/dl] | 5.13 (1.92–26.18) | 1.70 (0.80–1.35) | 0.004 |

ACS – Acute coronary syndrome, AMI – acute myocardial infarction, BMI – body mass index, DM – diabetes mellitus, HbA₁c – hemoglobin A₁c, hs-CRP – high-sensitivity C-reactive protein, IL-6 – interleukin-6, LAD – left anterior descending artery, LCX – left circumflex artery, MI – myocardial infarction, RCA – right coronary artery, SAP – stable angina pectoris, TCFA – thin-cap fibroatheroma, UAP – unstable angina pectoris, WBC – white blood cell.
Results

Patient characteristics

Because 3 (2 ACS patients and 1 SAP patient) of the 50 CVD patients were excluded owing to poor OCT imaging quality, we finally investigated 47 patients. Baseline characteristics of the patients are shown in Table I. Mean age was 67 ±11 years, and most of the patients were men. There were no significant differences in medical history, use of medicines, or cholesterol and hemoglobin A1c levels between the TCFA and non-TCFA groups. The incidence of AMI was higher in the TCFA group than in the non-TCFA group. Peripheral blood levels of hs-CRP and IL-6 in the TCFA group were relatively higher than those in the non-TCFA group (hs-CRP 2.62 (0.55–11.40) vs. 0.63 (0.40–1.35) mg/dl, \( p = 0.027 \); IL-6 5.13 (1.92–26.18) vs. 1.70 (0.80–1.35) pg/dl, \( p = 0.004 \), respectively) (Table I, Figure 3).

Blood samples were collected within hours from onset (mean 9 ±5 h) in all AMI patients.

Plaque morphology by optical coherence tomography

Twelve lesions were identified as TCFAs in our study, among which 10 were plaque ruptures. Thrombus was observed in 15 (43%) of 35 non-TCFA lesions. There was no difference in the minimum lumen area between the TCFA and non-TCFA groups (Table II).

Relationship between plaque morphology and serum biomarkers

Figure 3 shows the levels of inflammatory biomarkers. The log hs-CRP and IL-6 levels were higher in the TCFA group than in the non-TCFA group (log hs-CRP 0.87 (–0.96 to 0.87) vs. –0.47 (–0.92 to 0.87), log IL-6 10.0 (9.5 to 9.0) vs. 9.0 (8.5 to 9.0), \( p = 0.027 \) and 0.004, respectively) (Table I, Figure 3).
Table III. Univariate and multivariate logistic regression analyses for TCFA

| Variable               | Univariate logistic regression | Multivariable logistic regression |
|------------------------|-------------------------------|----------------------------------|
|                        | β-Coefficient | Value of p | β-Coefficient | Value of p | OR (95% CI) |
| Gender ratio           | 20.392         | 0.999      | –             | –           | –           |
| (male/female)          |                |            |               |             |             |
| WBC                    | 0.000          | 0.060      | –             | –           | –           |
| Statin use             | -1.083         | 0.202      | –             | –           | –           |
| SAP/ACS                | -2.260         | 0.008      | –             | –           | –           |
| Log hs-CRP             | 0.733          | 0.011      | –             | –           | –           |
| Log IL-6               | 1.126          | 0.005      | 0.970         | 0.023       | 2.638       |
|                        |                |            | (1.143–6.085) |             |             |

ACS – Acute coronary syndrome, AMI – acute myocardial infarction, CI – confidence interval, OR – odds ratio, SAP – stable angina pectoris, TCFA – thin-cap fibroatheroma, UAP – unstable angina pectoris, WBC – white blood cell.

to 0.30), p = 0.027; log IL-6, 1.63 (0.63 to 3.23) vs. 0.53 (–0.21 to 1.05), p = 0.005, respectively), although there was no difference in the white blood cell count between the 2 groups. In multivariate logistic regression analysis, the natural log of IL-6 was the only independent predictor for TCFA (odds ratio (OR) = 2.638, 95% confidence interval (CI) = 1.143–6.085, p = 0.023) (Table III). The ROC curve analysis confirmed that a log hs-CRP cutoff of 0.89 would detect TCFA with a 67% sensitivity and 60% specificity, and a log IL-6 cutoff of 2.56 would detect TCFA with a 75% sensitivity and 69% specificity (Figure 4). The area under the curve of log IL-6 was larger than that for log hs-CRP (0.783 vs. 0.715).

Discussion

Our study revealed a relationship between TCFAs in culprit lesions, as detected by OCT, not only with hs-CRP but also with IL-6 levels.

Recent OCT studies showed the relationships between plaque morphology and inflammatory factors. Li et al. [15] demonstrated an inverse linear correlation between fibrous cap thickness and plasma levels of inflammatory markers such as IL-18, hs-CRP, tumor necrosis factor-α, and peripheral white blood cell count. In that study, the only independent predictor for TCFA identified by OCT was hs-CRP. Bouki et al. [16] also reported that hs-CRP was the only independent predictor for plaque rupture in culprit lesions.

The CRP is mainly produced in the liver. It can be produced within the vascular smooth muscle of diseased coronary arteries, and it may directly lead to the expression of several mediators of the atherosclerotic process [17–19]. Liuzzo et al. [20] reported that patients with UAP who had higher CRP levels had more ischemic episodes in the hospital than patients with lower CRP levels. This finding suggested that coronary plaque instability could reflect circulating CRP. The CRP can provide important information, but is a nonspecific marker. It can be affected by systemic inflammatory reactions because it is mainly produced by the liver. Myocardial necrosis caused by infarction induces complement activation and free radical generation, which triggers a cytokine cascade and inflammatory reaction that consequently increases CRP production [21]. According to previous clinical studies [22, 23], CRP levels may begin to increase 6 h after an initial complaint, and a correlation between the extent of the CRP increase and the size of the infarction, as indicated by creatine kinase assay, was observed.

The IL-6 is a 26-kDa cytokine produced by many different cells in the body, including lymphocytes, monocytes, fibroblasts, vascular smooth muscle cells, and endothelial cells. It can stimulate...
the expression of tissue factor, monocyte chemo-
tactic protein-1, matrix-degrading enzyme, and
low-density lipoprotein receptors in macrophages
as well as aggregation of platelets and prolifera-
tion of vascular smooth muscle cells [24]. The IL-6
is also a proinflammatory biomarker that several
investigators have observed to be expressed in
human atherosclerotic lesions. Some reports have
shown that IL-6 levels were increased in a patient
with AMI [25–27] and that IL-6 levels were higher
in patients with UAP than in those with SAP
[28], but no correlation was observed between the
IL-6 level and size of the infarction as indicated
by creatine kinase [26–28]. Therefore, IL-6 has the
potential to reflect coronary plaque instability in
the presence of myocardial injury. Moreover, the
IL-6 levels in patients with UAP who had angina
at rest within the past 48 h were higher than in
patients who did not have angina at rest [24].
These findings suggest that IL-6 levels could cor-
relate with instability of the atheromatous plaque.

Our present study demonstrated that not only
hs-CRP but also IL-6 levels are associated with the
presence of TCFA detected by OCT. Furthermore,
IL-6 has higher sensitivity and specificity than
hs-CRP for the prediction of TCFA. Because of the
importance of screening for vulnerable plaques to
prevent cardiac adverse events and the need for
less invasive detection techniques [29], we sug-
ject that inflammatory biomarkers have potential
doing vulnerable plaques. In particular, IL-6
can provide surrogate information for risk stratifi-
cation of patients with ischemic heart disease.

Our study has several limitations. First, the
sample size in this study was relatively small. Sec-
don, we were able to detect TCFA by assaying
biomarkers, but we investigated only 2 biomark-
ers. Further studies are needed to find more sensi-
tive and specific biomarkers for detecting vulner-
able plaques [30, 31]. Third, it may be necessary
to observe not only culprit lesions but also other
coronary vessels to more precisely evaluate the
relationship between peripheral levels of biomark-
ers and coronary plaque vulnerability.

In conclusion, increased serum hs-CRP and IL-6
levels are associated with the presence of TCFAs in
culprit lesions detected by OCT. The relationship
between plaque instability, as detected by OCT,
and the levels of inflammatory biomarkers help us
better understand plaque vulnerability in patients
with coronary atherosclerosis.

Conflict of interest

The authors declare no conflict of interest.

References

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Mariscalco G, Lorusso R, Sessa F, et al. Imbalance be-
tween pro-angiogenic and anti-angiogenic factors in
rheumatic and mixomatous mitral valves. Int J Cardiol
2011; 152: 337-44.
3. Vasan RS. Biomarkers of cardiovascular disease: mo-
lecular basis and practical considerations. Circulation
2006; 113: 2335-62.
4. Puz P, Lasek-Bal A, Ziaja D, Kazibutowska Z, Ziaja K. In-
flammatory markers in patients with internal carotid
artery stenosis. Arch Med Sci 2013; 9: 254-60.
5. Burchardt P, Zawriski J, Zuchowski B, et al. Low-density
lipoprotein, its susceptibility to oxidation and the role of
lipoprotein-associated phospholipase A2 and carboxyl
ester lipase lipases in atherosclerotic plaque formation.
Arch Med Sci 2013; 9: 151-8.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-react-
tive protein and other markers of inflammation in the
prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
7. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and
the risk of coronary heart disease in men and women.
N Engl J Med 2004; 351: 2599-610.
8. Ridker PM, Rifai N, Stamper MJ, Hennekens CH. Plasma
concentration of interleukin-6 and the risk of future
myocardial infarction among apparently healthy men.
Circulation 2000; 101: 1767-72.
9. Kume T, Akasaka T, Kawamoto T, et al. Measurement of
the thickness of the fibrous cap by optical coherence
tomography. Am Heart J 2006; 152: 755-1-4.
10. Kume T, Akasaka T, Kawamoto T, et al. Assessment of
coronary arterial plaque by optical coherence tomog-
raphy. Am J Cardiol 2006; 97: 1172-5.
11. Koyama K, Yoneyama K, Mitalar T, et al. In-stent protru-
sion after implantation of a drug-eluting stent in a hon-
eycomb-like coronary artery structure: complete resolu-
tion over 6 months and the role of optical coherence
tomography imaging in the diagnosis and follow-up. J Am Coll Cardiol Intv 2014; 7: e39-40.
12. Virmani R, Burke AR, Kolodgie FD, Farb A. Vulnerable
plaque: the pathology of unstable coronary lesions.
J Interv Cardiol 2002; 15: 439-46.
13. Burke AR, Farb A, Malcom GT, Liang YH, Smialek J,
Virmani R. Coronary risk factors and plaque morphology
in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-82.
14. Kume T, Akasaka T, Kawamoto T, et al. Assessment of
coronary arterial thrombus by optical coherence tomog-
raphy. Am J Cardiol 2006; 97: 1713-7.
15. Li QX, Fu QQ, Shi SW, et al. Relationship between plas-
ma inflammatory markers and plaque fibrous cap thick-
ness determined by intravascular optical coherence
tomography. Heart 2010; 96: 196-201.
16. Bouki PK, Katsafadou GM, Chatzopoulos ND, Psy-
chan NS, et al. Inflammatory markers and plaque
morphology: an optical tomography study. Int J Cardiol
2012; 154: 287-92.
17. Baumann H, Gauldie J. Regulation of hepatic acute
phase plasma protein genes by hepatocyte stimulating
factors and other mediators of inflammation. Mol Biol Med 1990; 7: 147-59.
18. Verma S, Li SH, Badiwala MV, et al. Endothelin antago-
nism and interleukin-6 inhibition attenuate the proin-
erogenic effects of C-reactive protein. Circulation 2002;
105: 1809-6.
19. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory
effect of C-reactive protein on human endothelial cells.
Circulation 2000; 102: 2165-8.
20. Liuzzo G, Biasucci ML, Gallimore RJ, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
21. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
22. Kushner I, Broder ML, Karp D. Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J Clin Investig 1978; 61: 235-42.
23. Yip HK, Wu CJ, Chang HW, et al. Levels and values of serum high-sensitivity C-reactive protein within 6 hours after the onset of acute myocardial infarction. Chest 2004; 126: 1417-22.
24. Ikeda U, Ito T, Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol 2001; 24: 701-4.
25. Shah KP. Circulating markers of inflammation for vascular risk prediction: are they ready for prime time. Circulation 2000; 101: 1758-9.
26. Sturk A, Hack CE, Aarden LA, Brouwer M, Koster RR, Sanders GT. Interleukin-6 release and the acute-phase reaction in patients with acute myocardial infarction: a pilot study. J Lab Clin Med 1992; 119: 574-9.
27. Ikeda U, Ohkawa F, Seino Y, et al. Interleukin 6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol 1992; 24: 579-84.
28. Manten A, de Winter RJ, Minnema MC, et al. Procoagulant and proinflammatory activity in acute coronary syndrome. Cardiovasc Res 1998; 40: 389-95.
29. Gluba A, Bielecka-Dabrowa A, Mikhailidis DP, et al. An update on biomarkers of heart failure in hypertensive patients. J Hypertens 2012; 30: 1681-9.
30. Stepień M, Stepień A, Banach M, et al. New obesity indices and adipokines in normotensive patients and patients with hypertension: comparative pilot analysis. Angiology 2014; 65: 333-42.
31. Vespasiani-Gentilucci U, De Vincentis A, Argemi J, et al. Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography. Arch Med Sci 2013; 9: 635-9.